Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11)

BMC Structural Biology

Volumn 14, Issue 1, 2014, Pages

  Qiu, Wei ^a   Wang, Xiaonan ^a,b   Romanov, Vladimir ^a   Hutchinson, Ashley ^a   Lin, Andrés ^a   Ruzanov, Maxim ^a   Battaile, Kevin P ^c   Pai, Emil F ^a,d   Neel, Benjamin G ^a,b   Chirgadze, Nickolay Y ^a,d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ARGONNE NATIONAL LABORATORY   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PROTEIN TYROSINE PHOSPHATASE SHP 2; ASPARTIC ACID; CYSTEINE; GLYCINE; TYROSINE;

ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; GENE INTERACTION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HYDROGEN BOND; LEOPARD SYNDROME; NOONAN SYNDROME; PATHOGENESIS; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS; SURFACE CHARGE; WILD TYPE; ACUTE GRANULOCYTIC LEUKEMIA; DEUTERIUM HYDROGEN EXCHANGE; ENZYME ACTIVITY; HYPERTROPHIC CARDIOMYOPATHY; MASS SPECTROMETRY; MOLECULAR DYNAMICS; NEUROBLASTOMA; RISK FACTOR;

CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; HUMANS; HYDROGEN BONDING; LEOPARD SYNDROME; MODELS, MOLECULAR; MUTATION; NOONAN SYNDROME; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11;

EID: 84899062331     PISSN: None     EISSN: 14726807     Source Type: Journal    
DOI: 10.1186/1472-6807-14-10     Document Type: Article

References (46)

1. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Neel BG, Gu H, Pao L, Trends Biochem Sci 2003 28 6 284 293
2. Shp-2 tyrosine phosphatase: signaling one cell or many. Feng GS, Exp Cell Res 1999 253 1 47 54
3. Crystal structure of the tyrosine phosphatase SHP-2. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE, Cell 1998 92 4 441 450
4. Combinatorial control of the specificity of protein tyrosine phosphatases. Tonks NK, Neel BG, Curr Opin Cell Biol 2001 13 2 182 195
5. Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Barford D, Neel BG, Structure 1998 6 3 249 254
6. Structural determinants of SHP-2 function and specificity in Xenopus mesoderm induction. O'Reilly AM, Neel BG, Mol Cell Biol 1998 18 1 161 177
7. Germ-line and somatic PTPN11 mutations in human disease. Tartaglia M, Gelb BD, Eur J Med Genet 2005 48 2 81 96
8. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, Kucherlapati RS, Gelb BD, Nature genetics 2001 29 4 465 468
9. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, Pandit B, Oishi K, Martinelli S, Schackwitz W, Ustaszewska A, Martin J, Bristow J, Carta C, Lepri F, Neri C, Vasta I, Gibson K, Curry CJ, Siguero JP, Digilio MC, Zampino G, Dallapiccola B, Bar-Sagi D, Gelb BD, Nat Genet 2007 39 1 75 79
10. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, Li L, Yassin Y, Tamburino AM, Neel BG, Kucherlapati RS, Nat Genet 2007 39 1 70 74
11. Germline KRAS mutations cause Noonan syndrome. Schubbert S, Zenker M, Rowe SL, Boll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, Rauch A, Niemeyer CM, Shannon K, Kratz CP, Nat Genet 2006 38 3 331 336
12. A restricted spectrum of NRAS mutations causes Noonan syndrome. Cirstea IC, Kutsche K, Dvorsky R, Gremer L, Carta C, Horn D, Roberts AE, Lepri F, Merbitz-Zahradnik T, Konig R, Kratz CP, Pantaleoni F, Dentici ML, Joshi VA, Kucherlapati RS, Mazzanti L, Mundlos S, Patton MA, Silengo MC, Rossi C, Zampino G, Digilio C, Stuppia L, Seemanova E, Pennacchio LA, Gelb BD, Dallapiccola B, Wittinghofer A, Ahmadian MR, Tartaglia M, Zenker M, Nat Genet 2010 42 1 27 29
13. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Cordeddu V, Di Schiavi E, Pennacchio LA, Ma'ayan A, Sarkozy A, Fodale V, Cecchetti S, Cardinale A, Martin J, Schackwitz W, Lipzen A, Zampino G, Mazzanti L, Digilio MC, Martinelli S, Flex E, Lepri F, Bartholdi D, Kutsche K, Ferrero GB, Anichini C, Selicorni A, Rossi C, Tenconi R, Zenker M, Merlo D, Dallapiccola B, Iyengar R, Bazzicalupo P, Gelb BD, Tartaglia M, Nat Genet 2009 41 9 1022 1026
14. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, Martinelli S, Pogna EA, Schackwitz W, Ustaszewska A, Landstrom A, Bos JM, Ommen SR, Esposito G, Lepri F, Faul C, Mundel P, López Siguero JP, Tenconi R, Selicorni A, Rossi C, Mazzanti L, Torrente I, Marino B, Digilio MC, Zampino G, Ackerman MJ, Dallapiccola B, Tartaglia M, Gelb BD, Nat Genet 2007 39 8 1007 1012
15. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Razzaque MA, Nishizawa T, Komoike Y, Yagi H, Furutani M, Amo R, Kamisago M, Momma K, Katayama H, Nakagawa M, Fujiwara Y, Matsushima M, Mizuno K, Tokuyama M, Hirota H, Muneuchi J, Higashinakagawa T, Matsuoka R, Nat Genet 2007 39 8 1013 1017
16. Noonan syndrome and related disorders: genetics and pathogenesis. Tartaglia M, Gelb BD, Annu Rev Genomics Hum Genet 2005 6 45 68
17. Occurrence of myeloproliferative disorder in patients with Noonan syndrome. Bader-Meunier B, Tchernia G, Mielot F, Fontaine JL, Thomas C, Lyonnet S, Lavergne JM, Dommergues JP, J Pediatr 1997 130 6 885 889
18. SHP-2 and myeloid malignancies. Tartaglia M, Niemeyer CM, Shannon KM, Loh ML, Curr Opin Hematol 2004 11 1 44 50
19. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Loh ML, Vattikuti S, Schubbert S, Reynolds MG, Carlson E, Lieuw KH, Cheng JW, Lee CM, Stokoe D, Bonifas JM, Curtiss NP, Gotlib J, Meshinchi S, Le Beau MM, Emanuel PD, Shannon KM, Blood 2004 103 6 2325 2331
20. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Chan G, Kalaitzidis D, Neel BG, Cancer Metastasis Rev 2008 27 2 179 192
21. PTPN11 mutations in LEOPARD syndrome. Legius E, Schrander-Stumpel C, Schollen E, Pulles-Heintzberger C, Gewillig M, Fryns JP, J Med Genet 2002 39 8 571 574
22. The leopard (multiple lentigines) syndrome revisited. Gorlin RJ, Anderson RC, Moller JH, Laryngoscope 1971 81 10 1674 1681
23. High incidence of malformation syndromes in a series of 1,073 children with cancer. Merks JH, Caron HN, Hennekam RC, Am J Med Genet A 2005 134A 2 132 143
24. Acute myelomonocytic leukemia in a boy with LEOPARD syndrome (PTPN11 gene mutation positive). Ucar C, Calyskan U, Martini S, Heinritz W, J Pediatr Hematol Oncol 2006 28 3 123 125
25. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. Marin TM, Keith K, Davies B, Conner DA, Guha P, Kalaitzidis D, Wu X, Lauriol J, Wang B, Bauer M, Bronson R, Franchini KG, Neel BG, Kontaridis MI, The Journal of clinical investigation 2011 121 3 1026 1043
26. Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling. Krenz M, Yutzey KE, Robbins J, Circ Res 2005 97 8 813 820
27. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Araki T, Mohi MG, Ismat FA, Bronson RT, Williams IR, Kutok JL, Yang W, Pao LI, Gilliland DG, Epstein JA, Neel BG, Nat Med 2004 10 8 849 857
28. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Fragale A, Tartaglia M, Wu J, Gelb BD, Hum Mutat 2004 23 3 267 277
29. Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. Keilhack H, David FS, McGregor M, Cantley LC, Neel BG, J Biol Chem 2005 280 35 30984 30993
30. Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia. Niihori T, Aoki Y, Ohashi H, Kurosawa K, Kondoh T, Ishikiriyama S, Kawame H, Kamasaki H, Yamanaka T, Takada F, Nishio K, Sakurai M, Tamai H, Nagashima T, Suzuki Y, Kure S, Fujii K, Imaizumi M, Matsubara Y, J Hum Genet 2005 50 4 192 202
31. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Tartaglia M, Martinelli S, Stella L, Bocchinfuso G, Flex E, Cordeddu V, Zampino G, Burgt I, Palleschi A, Petrucci TC, Alsorcini M, Schoch C, Foa R, Emanuel PD, Gelb BD, Am J Hum Genet 2006 78 2 279 290
32. Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1. Hanna N, Montagner A, Lee WH, Miteva M, Vidal M, Vidaud M, Parfait B, Raynal P, FEBS Lett 2006 580 10 2477 2482
33. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG, J Biol Chem 2006 281 10 6785 6792
34. Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome. Krenz M, Gulick J, Osinska HE, Colbert MC, Molkentin JD, Robbins J, Proc Natl Acad Sci U S A 2008 105 48 18930 18935
35. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. Wu X, Simpson J, Hong JH, Kim KH, Thavarajah NK, Backx PH, Neel BG, Araki T, J Clin Invest 2011 121 3 1009 1025
36. PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots? Lauriol J, Kontaridis MI, Trends Cardiovasc Med 2011 21 4 97 104
37. Identification of a human src homology 2-containing protein-tyrosine- phosphatase: a putative homolog of Drosophila corkscrew. Freeman RM Jr, Plutzky J, Neel BG, Proc Natl Acad Sci U S A 1992 89 23 11239 11243
38. Enabling IMAC purification of low abundance recombinant proteins from E. coli lysates. Magnusdottir A, Johansson I, Dahlgren LG, Nordlund P, Berglund H, Nature methods 2009 6 7 477 478
39. Integration, scaling, space-group assignment and post-refinement. Kabsch W, Acta crystallographica Section D, Biol Crystallogr 2010 66 Pt 2 133 144
40. Features and development of Coot. Emsley P, Lohkamp B, Scott W, Cowtan K, Acta Crystallogr D Biol Crystallogr 2010 66 4 486 501
41. Buster 2.10.0. Bricogne GBE, Brandl M, Flensburg C, Keller P, Paciorek W, Roversi P, Sharff A, Smart OS, Vonrhein C, Womack TO, 2.10.0 edn Cambridge: United Kingdom: Global Phasing Ltd 2011
42. Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Digilio MC, Conti E, Sarkozy A, Mingarelli R, Dottorini T, Marino B, Pizzuti A, Dallapiccola B, Am J Hum Genet 2002 71 2 389 394
43. Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2. Eck MJ, Pluskey S, Trub T, Harrison SC, Shoelson SE, Nature 1996 379 6562 277 280
44. PTP1B: from the sidelines to the front lines! Tonks NK, FEBS Lett 2003 546 1 140 148
45. Functional effects of PTPN11 (SHP2) mutations causing LEOPARD syndrome on epidermal growth factor-induced phosphoinositide 3-kinase/AKT/glycogen synthase kinase 3beta signaling. Edouard T, Combier JP, Nedelec A, Bel-Vialar S, Metrich M, Conte-Auriol F, Lyonnet S, Parfait B, Tauber M, Salles JP, Lezoualc'h F, Yart A, Raynal P, Mol Cell Biol 2010 30 10 2498 2507
46. Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations. Yu ZH, Xu J, Walls CD, Chen L, Zhang S, Zhang R, Wu L, Wang L, Liu S, Zhang ZY, J Biol Chem 2013 288 15 10472 10482